Sprint Bioscience

Executive Summary

Sprint Bioscience is a Swedish pharmaceutical company specializing in fragment-based drug discovery for oncology. The company aims to address difficult-to-treat cancers by developing innovative small-molecule drug candidates in a resource-efficient manner. Its business model focuses on out-licensing preclinical programs to global pharmaceutical companies, thereby generating value through milestone payments and royalties. With a strong foundation in fragment-based lead generation, Sprint Bioscience has built a pipeline of early-stage assets targeting key cancer pathways. Despite being in the preclinical stage, the company has demonstrated the ability to attract interest from larger pharma partners. The upcoming catalysts include the completion of lead optimization and candidate selection for its most advanced programs, which could trigger partnership discussions. However, execution risks remain high given the early-stage nature of the pipeline and the competitive oncology landscape.

Upcoming Catalysts (preview)

• Q4 2026Lead optimization completion for lead program40% success
• Q2 2027New partnership or out-licensing deal30% success
• Q3 2026Presentation of preclinical data at major conference60% success